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ABSTRACT
As a concept sentinel lymph node biopsy seems attractive
in that it attempts to identify the first lymph node, rather
than the nearest node, draining a particular anatomic area
where a tumour has arisen. Pathological assessment can
then indicate whether metastases are present and the
procedure is either a strong prognostic indicator or
possibly therapeutic in itself. These comments apply to
any tumour type, but with melanoma the pathological
procedure is more problematic and any benefits above
prognosis and staging are not universally accepted. The
procedure does give accurate staging without the extra
morbidity of regional node dissection and many patients
gain psychological support from the information gained.
POTENTIAL BENEFITS OF SENTINEL LYMPH NODE
BIOPSY FOR MELANOMA
Excision of the sentinel lymph node (SLN) enables
a prognostic assessment to be made that is more
powerful than thickness measurements on the
primary.1 2 This in itself is sufficient, to many, to
justify the procedure since it has low morbidity.3
The SLN status is an important criterion for entry
into clinical trials and therefore until a clear
effective systemic therapy is established SLN
biopsy (SLNB) will have importance and the SLN
status may be the threshold to entry into a
treatment programme.
The initial reason for development of SLNB was
to enable selection of patients more likely to
receive benefits from regional node dissection
(RND). It had already been shown that RND
was not effective on unselected patients but in the
absence of alternatives the surgical treatment
option was retained. The SLNB seemed a way of
directing RND to a group of patients more likely to
benefit from wide excision of nodes. This remains
the usual procedure, although evolution towards
offering RND to an even more restricted group of
patients is proceeding. Whether SLNB by itself is of
therapeutic benefit is not yet established. There is a
suggestion of prolongation of disease-free survival
for SLNB patients as compared with observation
followed by RND only when clinical evidence of
metastases develops. Prolongation of overall survi-
val has not yet been demonstrated but longer
follow-up may reveal this.2
POTENTIAL PROBLEMS OF SLNB
Any disadvantages of SLNB are also not estab-
lished. The anxieties about an increase in ‘‘in
transit’’ metastases4 5 have not been upheld.6 7 The
theoretical concern about removal of what is likely
to be the first line of immunological defence still
requires further study. A suggested alternative
procedure is high-grade ultrasound,8 but 4.5 mm
is the smallest size that can be consistently
detected with this technique and the majority of
metastases in SLN for melanoma are smaller than
that and therefore this alternative does not appear
acceptable as a substitute for SLNB. The SLNB
procedure has some associated morbidity but this
is much less than for RND, and at least 70% of
patients with melanoma will avoid this morbidity
by having the lesser procedure. The National
Institute for Health and Clinical Excellence
(NICE) report on skin tumours9 has concluded
that SLNB has merit for staging, and that it should
continue to be done in existing centres as part of
clinical trials, but has not wholeheartedly recom-
mended SLNB for all melanoma. This recommen-
dation is in spite of the current paucity of suitable
trials into which to enter patients. The NICE
advice may need modification in the light of the
recent report of MSLT-1 since some prolongation
of disease-free survival has been demonstrated2 and
improved overall survival cannot be ruled out.
SURGICAL PROCEDURES EFFECTING
PATHOLOGICAL ASSESSMENT
The identification of the SLN by the surgeon
should be based on preoperative lymphoscintigra-
phy and intraoperative injection of vital blue dye
and radiocolloids. The lymphoscintigraphy demon-
strates the direction of the lymph drainage from
any cutaneous site and enables the first or sentinel
lymph nodes in each basin to be identified and
marked on the overlying skin. There is some
variation in definitions of SLN and so there may
be variation in the numbers of SLN excised
between surgeons or between centres.
The SLN should be excised with a cuff of fat and
without trauma to the node. Examination of the
subcapsular zone of the SLN is most likely to reveal
metastases and so it is important that this should
not be damaged by the surgery.10 Confirmation of
what is a true SLN may be obtained by using
carbon dye injected at the primary site. This tends
to be localised in the area most likely to contain
metastases and its presence confirms the node as a
true SLN. Unfortunately this carbon preparation is
not available in all countries. Where the surgeon
sees the afferent lymphatics with the blue dye he
can use a ligature to identify this aspect of the node
so that the pathologist is aware of the orientation
of the node, and this therefore facilitates the slicing
through the median plane.
HISTOPATHOLOGICAL AND PATHOBIOLOGICAL
PECULIARITIES OF MELANOCYTIC TUMOURS
AFFECTING INTERPRETATION OF SLN
In contrast to interpretation of SLN for other
malignancies, melanoma presents extra difficulties
due to its tendency to metastasise in small groups
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or even single cells, which on conventional H&E staining are
similar to other cells normally present in lymph nodes at least at
scanning magnification. The assessment of the lymph node
must be designed to detect as many as possible of these
metastases. To detect all of them would involve serial sectioning
of the SLN to extinction resulting in thousands of sections per
node. This is clearly not practicable and a balance between
workload and efficiency is required and several procedures have
been developed.
PATHOLOGICAL PROCEDURES
Dissection
Dissection of the SLN can be by random parallel ‘‘bread loaf’’
slicing11 or single slicing through the central plane (bivalve
technique).12
Since Cochran, in an early study,13 showed that the majority
of metastases are in a central plane (see fig 1), the bivalve
technique, in which a slice is made through the convex capsule
and the hilum to reveal the maximum cut surface area, has been
adopted by us.14 The alternative technique recommended by
Starz et al11 consists of slicing the SLN at 2 mm intervals. It is
attractive in that it does not depend on the slightly difficult
identification of a central plane and also in that it does not
require multiple sections on each slice. However, in larger nodes,
there may be a need for several blocks.
On balance we have preferred to use the bivalving approach,
but using some dissection of the lymph node from the
surrounding fat followed by a combined visual assessment and
palpation to identify the central plane through which the node
is bisected.
Sectioning and staining
Further options exist in the sectioning and staining of the
bivalved node. Cochran12 recommended serial sections from the
two mid-plane surfaces stained with a combination of H&E and
melanocyte markers (S100, HMB45, Melan A). Starz11 examined
only two sections from each block dissected in a different way,
and used H&E and immunohistochemistry. Both of these
procedures detected metastases in 15–20% of patients.
Since immunohistochemistry increases the detection rate of
metastases by at least 10%15 we have used it from the beginning.
The particular antibody used depends on local preference. We
have tried HMB45, MelanA, MiTF and S100. Melan A and
HMB45 are widely used but they can be criticised as being less
sensitive; however, on the other hand they have the advantage
of being more specific. S100 has been chosen as the first-line
antibody since it is the most sensitive, the least demanding
technically, and the cheapest. However, it does require the
pathologist to gain experience in its interpretation, particularly
in distinguishing melanocytes from clumps of dendritic cells.
We have overcome this rare problem by always having
unstained adjacent sections for more specific antibodies in
reserve for use in more problematic cases. We use Melan A most
often for this confirmatory purpose. We have found HMB45
positivity in only 70% of melanomas and therefore do not
regard it as sufficiently sensitive. A cocktail of antibodies
including Melan A, HMB45, S100 and tyrosinase such as Pan
Mel+ (Biocare Medical, Concord, California, USA) has high
sensitivity and specificity but is more expensive and technically
more demanding. With experience, S100 has the highest
sensitivity and particularly in combination with diaminobenzi-
dine chromogen even single cells can be identified on screening
magnification and confirmed on the adjacent H&E. This enables
distinction from other potentially positive cells such as dendritic
cells and nerves. We assess the same cells on immediately
adjacent sections stained with H&E. Unless we are convinced
that the immunohistochemistry positivity corresponds with a
cell with cytological features of a melanocyte, we do not regard
the SLN as positive.
Melanophages may sometimes be identified without mela-
nocytes in the SLN and it could be speculated that these
features represent intranodal regression, but the melanophages
could equally well represent drainage of melanophages from the
primary melanoma. These are particularly numerous when the
primary melanoma shows features of regression.
Balancing extended sectioning against reverse transcription-PCR
In the early stages of development of SLN pathology protocols,
the possibility of using molecular techniques such as reverse
transcription (RT)-PCR on fresh tissue instead of histology was
considered. Positivity in SLN for melanoma using tyrosinase and
or MART-1 or gp100 was found to be much higher than that
obtained using histology, even up to 72% positive.16 This high
positivity far exceeded what would be expected from our
knowledge of the natural history of melanoma unless the
selection of cases was highly selected in favour of extremely
poor prognosis patients. However the comparison between
histology and molecular techniques was not adequately
controlled, most obviously in that the lymph nodes were
divided in an unspecified way and the separate parts assessed by
only one of the two techniques. This took no account of the
distribution of the metastases in the nodes.
We decided that the role of molecular biology needed to be
evaluated in a more controlled manner,14 and we found that a
positivity of 45% with RT-PCR on frozen sections did exceed
what was obtained from immediately adjacent sections stained
conventionally (18% positive), but that the discrepancy could be
explained partly by the presence of naevus cells, which would
also give a positive RT-PCR result, and partly by the presence of
further melanoma deeper in the node only detected by more
sections.
We achieved a detection rate of 33.8% by extending the
sectioning protocol to six pairs of sections at 50 mm intervals.
Each pair was stained with H&E and S100. Other unstained
spare sections were taken at each 50 mm step. Further levels
Figure 1 Metastases of melanoma are said to occur close to the
median plane of the sentinel lymph node and therefore bivalving, as
shown, and embedding face down in the cassette are recommended.
My approach
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deeper than the sixth pair produced only a minimal improve-
ment in detection rate and therefore the six pairs at 50 mm
intervals protocol was adopted by us as a reasonable balance
between workload and sensitivity.14
The detection rate of 33.8% was still below 45% detected by
RT-PCR but this is explained almost entirely by the presence of
naevus cells. Others17 have suggested that this protocol is too
labour intensive or expensive. More importantly the significance
of the additional metastases needs to be established.
We do not regard the extra work as excessive since in more
than 70% of SLN that are negative only seven slides need to be
examined per lymph node. This is achieved by using S100 as a
preliminary stain for scanning and one H&E to rule out other
pathology. In the 30% of cases that are positive, more detailed
assessment is required. Occasional melanomas are S100 negative
(1% in our experience), but metastases are still identified easily
as a negative or clear area against the blue counterstained
background.
The only variation in the sectioning protocol occurs when
lymph nodes are unusually rounded rather than approximately
reniform. In those thicker lymph nodes we use a wider step
between the pairs of stained sections, increasing it from 50 mm
to 75 or 100 mm.
It may be that the protocol we have adopted14 in the long
term may be shown to be excessively rigorous since Van Akkooi
et al18 have shown that metastases ,0.1 mm are not associated
with further disease. However we consider that all metastases
however small have yet to be shown not to be capable of
progressing to more aggressive disease even after many years.
We have some experience of metastases remaining small and
localised in lymph nodes for several years after excision of the
primary melanoma. This is presumably the explanation of how
some melanoma metastases occasionally progress 10 or more
years after excision of the primary. It remains to be shown
whether some melanoma metastases are not capable of
progression by reason of different biology related to their
genetic profile, and therefore at least until that is proved and
such cases are identifiable, detection of as many as possible of
metastases should be the aim. This is supported by finding that
so-called isolated tumour cells in groups less than 0.2 mm are
associated with a lower overall survival.27
At least for the foreseeable future we recommend the protocol
as outlined in table 1 using S100 as a screening stain so that the
procedure is not too time consuming. RT-PCR is not ideal at
least for detection of metastases but work of Hoon et al19 and
Chew et al (unpublished) indicate that it may be useful in
providing additional prognostic information.
Naevus cells in SLN
One of the main difficulties in interpretation of SLN is the
presence of benign naevus cells. These are detected by S100 but
are almost always negative with HMB45, so that marker can be
used to distinguish naevus cells from metastatic melanoma.10
However, not all melanomas are positive with HMB45 (70% in
our experience) so that negativity is not a confirmation of
benign nature.
More importantly, naevus cells can be distinguished from
metastases by their site and cytology. We have assessed the SLN
from 2005 patients with cutaneous melanoma, and 14% of
them contained naevus cells mostly in the substance of the
fibrous capsule but occasionally in the fibrous trabeculae. The
cells are usually characteristically naevoid with small dense
nuclei or little cytoplasm. However, very occasionally, collec-
tions of naevoid cells are quite large so that they appear to
encroach into the adjacent lymph node. In those cases, while
nuclei are still highly uniform, nucleoli can become evident. In
these rare difficult cases we use HMB45 (as recommended by
Murray et al10) and MIB1. The HMB45 status is an important
guide but sometimes a more definite conclusion is achieved with
MIB1. Naevus cells should show no positivity with this stain,
but melanoma would be expected to show at least some positive
nuclei.
The interpretation of MIB1 can be difficult in lymph nodes
because of the high proportion of positivity in surrounding
lymphocytes. P16 can be used in a similar way being usually
positive in naevus cells and lost in melanoma.
We have identified naevus cells in 279 SLN patients. Sixty-
two (22.2%) of these were associated with melanoma metas-
tases but the majority (217) were not.
WHICH PATIENTS SHOULD BE OFFERED SLNB
The criteria of the primary melanoma that are used to justify
performing SLNB are not standardised but most commonly a
minimum thickness of 1 mm has been used. Others have
suggested that there is no benefit in performing SLNB on
patients with melanomas thicker than 4 mm since these are
already known to have a bad prognosis. However, we would
argue that a large proportion (40%) of the thick melanomas still
have long-term survival and therefore the SLN can be used to
attempt to identify that particular group. We originally
considered that any patients with a melanoma in vertical
growth phase should be offered SLNB and we did identify
several patients with melanomas less than 1 mm down to
0.6 mm thickness that had metastasised. Nevertheless, the
number of such cases was a small proportion of the total and
therefore began to restrict offering SLNB to patients with
melanoma thicker than 1 mm. Gimotty et al20 have suggested
that thin melanomas (,1 mm) can be graded in risk according
to their mitotic counts and the gender of the patient. Males
with thin and invasive mitotically active melanomas are said to
have a 31% risk of metastasis and females a 13% risk. Therefore
we have begun to offer SLNB to patients with thin melanomas
and dermal mitoses that by definition are in vertical growth
phase.
Regression has also long been considered as an important
feature of melanomas, with implications of an adverse effect on
prognosis by some. This effect is not accepted universally and
there are roughly equal numbers of studies who regard
regression as having an unfavourable effect on survival as those
who consider it to have no or even a favourable effect.21
Nevertheless prognostic tables22 showed regression as a poor
prognostic factor and for that reason we did use it as a criterion
for offering SLNB.
Our own studies23 comparing melanoma patients with or
without regression in terms of SLN status, as a surrogate for
survival, showed as one might expect intuitively that regression
appeared to confer benefit to the patient, therefore we have
discontinued accepting regression as a criterion.
Morton et al2 have identified some prolongation of disease-
free survival with SLNB on melanomas with thickness between
1.2 and 4 mm but this does not imply that SLNB should only be
offered to patients with this range of thickness of melanoma
since the staging benefits also apply to those outside this group.
At this stage we think it appropriate to offer SLNB to all
patients with melanoma over 1.0 mm in thickness and to those
patients with thinner invasive melanomas in which mitoses are
identified in the dermal component unless there are other
clinical features that override this decision.
My approach
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MULTICENTRE SLN TRIALS
The first multicentre SLN trial (MSLT-1) has made a
preliminary report.2 In 1269 patients, this trial has shown that
SLNB with immediate RND for positive cases had a 4.8%
improvement in disease-free survival compared with no SLNB
and RND only on clinical evidence of metastasis.
The SLN status was confirmed as a potent prognostic factor
in that positive nodes conferred a 5-year survival rate of 72.3%
on the patients compared with 90.2% in patients with negative
SLN. No overall survival benefit was noted at 5-year follow-up.
This does not exclude the possibility of survival advantage being
demonstrated after longer follow-up since metastases from
thinner melanomas tend to occur later if at all.
The second multicentre SLN trial (MSLT-2) proposes to
evaluate whether it is necessary to proceed to RND in all
patients with positive SLN irrespective of the tumour burden,
and also to further examine the role of RT-PCR positivity in
histologically negative SLN. Some cases that are histologically
negative but positive on RT-PCR will still enter the trial.
The Sunbelt melanoma trial, which is another multicentre
study,24 emphasises the prognostic and staging value of SLNB
histology and also proposes to evaluate the role of RT-PCR in
assessment of SLN, but has not yet concluded its study. It has
reported a definition of SLN based on the ratio of radioactivity
in a node to that in the background. The latter should be 10% or
less of that in the SLN.
The Sunbelt trial has not identified factors in the SLN
metastases that enable prediction of metastases elsewhere and
therefore they advocate completion lymphadenectomy for every
patient with a positive SLN. They have noted a lower rate of
metastases to SLN in older patients despite the shorter survival
in the same group, suggesting that the biology of melanomas of
younger patients is often different from that of older patients,
with the latter showing greater tendency to haematogenous
metastases.
This is supported by the findings of Viros et al 25 in which
patients under 55 years were much more likely to have
melanomas with BRAF mutation than older patients. This
supports the growing support for the idea that melanoma is not
one diagnosis but a collection of melanocytic tumours with
different behaviours.
A FUTURE ROLE FOR RT-PCR
The MSLT-2 proposals have been stimulated in part by the
observations of further RT-PCR studies19 that indicate that RT-
PCR positive, histologically negative SLN have a worse
prognosis than those that are negative by both techniques.
Our recent studies (unpublished) also suggest that nodal
metastases detected by melanoma-specific markers such as
MAGE-3 revealed by RT-PCR on paraffin-embedded tissue from
SLN gives an added dimension to the prognosis beyond that
which can be obtained with histology alone. However the
process is laborious, therefore potentially expensive, and only
dissects out an additional group of poorer prognosis patients
from those 70% or so who are negative by histology. Rather
than perform this additional assessment on the whole 70% of
SLN that are negative, there is a need for a way of focussing on
those within that group who are more likely to be positive. This
would make this procedure more likely to be acceptable. For
example, perhaps RT-PCR would be predictably negative in
SLN-negative patients who were thinner than say 1.2 mm and
had no mitoses in the dermis, or were of a histological type with
suspected better prognosis such as spindle cell melanomas, or
had a diffuse and intense tumour-infiltrating lymphocyte
response.
Conversely SLN-negative cases that are histologically nega-
tive, but have a high mitotic count, would be expected to be
more likely to be positive with RT-PCR.
IMPROVEMENT OF PREDICTIVE ACCURACY OF HISTOLOGICAL
ASSESSMENT OF SLN ACCORDING TO ‘‘TUMOUR BURDEN’’
A straightforward record of presence or absence of metastases in
SLN has great prognostic value,1 but several authors have
considered whether specific features of the metastases or their
distribution may give more precise prognostic information.
Starz et al11 described an index derived from the depth of the
metastases from the capsule and the number of slices involved.
This index enabled a prediction of the status of the rest of the
lymph nodes in the same basin to be made with considerable
accuracy. Cochran12 was able to provide increased accuracy of
survival prediction by using a relative tumour area calculation,
based on some computer-facilitated measurement and calcula-
tions.
Our group26 noted a correlation between the microanatomic
distribution of the metastases in the SLNB and the presence of
additional metastases in the RND. Those patients in whom the
metastases were entirely subcapsular (fig 2) were found not to
have any metastases in the nodes of the subsequent RND. The
subcapsular pattern was seen in approximately 30% of all
positive SLN. More recently Van Akkooi et al18 showed that
metastases ,0.1 mm in maximum dimension, irrespective of
site, were not associated with further metastases or any
evidence of tumour progression. Govindarajan et al27 supported
similar findings in noting that patients with metastases
,0.2 mm maximum dimension did not have positivity in their
RND. There have been no recurrences in this group although
Table 1 Sequence of sectioning and staining for sentinel
lymph node for melanoma
Section Treatment
Section 1 (first full section) H&E
Section 2 S100
Section 3 Spare
50 mm gap (+50 mm)
Section 4 H&E
Section 5 S100
Section 6 Spare
Section 7 Spare
Section 8 Spare
Section 9 Spare
50 mm gap (+100 mm)
Section 10 H&E
Section 11 S100
Section 12 Spare
50 mm gap (+150 mm)
Section 13 H&E
Section 14 S100
Section 15 Spare
50 mm gap (+200 mm)
Section 16 H&E
Section 17 S100
Section 18 Spare
50 mm gap (+250 mm)
Section 19 H&E
Section 20 S100
In large or round lymph nodes, the 50 mm gap may be increased up
to a maximum of 100 mm.
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the follow-up period was short. These findings require further
study as the number of such cases that were not subcapsular
was very small. In addition28 Scheri et al have noted that
metastases ,0.2 mm in maximum dimension have a signifi-
cantly higher risk of melanoma-specific death than SLN-
negative patients thereby questioning the assumption that
small metastases have limited significance.
These assessments of tumour burden all have merits, but
whether one is more accurate or appropriate than another is not
finally decided. All of them depend on careful examination of all
available sections since metastases are not necessarily present in
all.10 The Starz technique is perhaps most simple to assess being
a measure from the capsule to the deepest metastasis. However
one could ask from which part of the capsule does one measure.
Logically it should be from the afferent aspect, but this is not
always obvious.
Van Akkooi et al recommends the maximum dimensions of
the largest deposit; this sounds straightforward but it needs to
be understood that they mean the largest cohesive groups of
cells, even though that may be only one of many, each of them
showing only slight separation from each other.
The location of the metastases in our hands gives more
reliable information, very easily assessed, in that subcapsular
metastases are only very rarely associated with metastases in
the rest of the nodes in the same basin. Even so, the definition of
subcapsular site needs to be considered carefully. Subcapsular
sinuses are not clearly visible and metastases in that zone are
not usually identifiable as in a lumen. Their subcapsular zone
location is important, with the configuration of the deposit
being reasonably smooth, that is with no irregular projections
on the parenchymal aspect.
On the basis of these studies it seems reasonable to presume
that prognosis based on SLN can be refined, and that low
volume, small or subcapsular metastases may not need to be
followed by RND, although the criteria accepted may require
further refinement. Whether these small or subcapsular
metastases are precursors to larger tumours or represent a
different character of metastases with more indolent growth
properties remains to be established. It seems likely to us that
they represent a mixture of early but potentially aggressive
metastases with some more indolent ones.
In the meantime the European Organization for Research and
Treatment of Cancer (EORTC) has suggested a clinical trial of
melanoma patients with SLN metastases confined to the
subcapsular zone or less than 0.1 mm in maximum dimension
irrespective of site. These will be followed by observation for
5 years in the first instance. If these metastases are not
associated with further disease then there would be some
validation of a more selective approach to RND. It would also
put more pressure on pathologists to assess the SLNB in greater
detail. At the moment these assessments are performed only as
part of studies or trials, but virtually all patients having SLNB
are in that category since the procedure is to a large extent still
being evaluated.
SUMMARY: PART 1
Proposals for SLN assessment
On the basis of our work and other published work we suggest
that SLN for melanoma should be bivalved according to
Cochran’s method. The resulting paraffin-embedded blocks
should be sectioned in our opinion in a stepwise manner.
We currently use 50 mm steps producing six pairs of sections
to an approximate total depth of 0.3–0.4 mm. There is an
argument to make the steps wider or less numerous,29 but
bearing in mind the small size of many metastases and our lack
of certainty on the critical dimension of the metastases we feel
this change in protocol needs to be done in a systematic way.
Van Akkooi et al18 suggest metastases ,0.1 mm diameter can be
ignored. The EORTC observation study, in part, is intended to
validate that observation and therefore we will continue with
the existing EORTC protocol of six pairs of sections at 50 mm
intervals at least until that study reports.
We have strongly recommended the need for immunohisto-
chemistry in the assessment partly because the detection rate is
then higher and partly because the recognition of metastases is
much facilitated, making the pathologist’s task less onerous.
Whether S100 or Melan A is used is a matter of personal choice.
It is wise to retain some unstained sections at each level for
problematic cases.
The features that should be recorded are not only the
presence of metastases but their site and size.
A metastasis in a subcapsular site but with a markedly
irregular aspect towards the parenchyma or single cells breaking
away from the main metastasis should not be regarded as being
entirely subcapsular in site.
Other measurements on which further refinements of
management may be based are the depth of the metastasis
from the capsule to its deepest point, and the maximum
dimension of the largest deposit. Van Akkooi et al18 have
suggested that this last dimension should be applied only to
cohesive groups of cells rather than looser aggregates. Groups of
10 cells or less are already regarded by that group as negative.
Others are taking a more cautious line and would prefer to
await the results of more studies on this point. Since, at least in
the UK, the SLNB procedure is not regarded as standard, and in
all countries is being carefully evaluated, it is not suggested that
the pathological assessments should simply be loaded onto
pathology departments without careful consideration of the
labour or cost implications. Furthermore, it is important that
committed pathologists are involved in the reporting of SLN to
ensure the reproductibility of the detailed assessments currently
being undertaken in multicentre trials.
Figure 2 Screening of sentinel lymph node stained with S100
facilitates identification of metastatic melanoma. Distinction from
dendritic cells, seen lower left, is made on the basis of cytology, with the
dendritic cells having a poorly defined outline and smaller nuclei. The
H&E-stained adjacent section enables confirmation of the cytological
features and the site of the metastasis—in this case subcapsular.
My approach
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We accept that SLNB for melanoma is in a phase of
assessment and therefore we believe that the criteria we have
set out and any new criteria need to be evaluated critically
before discarding or adopting them formally as recommenda-
tions for general application.
SUMMARY: PART 2
Probable further developments
A lower threshold thickness of the primary melanoma for entry
to SLNB could be considered as well as greater reliance on
mitotic activity, particularly in males, and perhaps in due course
on genetic profile. Since currently at least 70% of patients
having SLNB have negative results, a greater focus on those who
are more likely to be positive is predicted. This may be achieved
by changes to the criteria of the primary melanoma used to
justify performing SLNB.
It is also possible that RND will be offered to only those
patients with metastases involving a parenchymal site or above
a certain size.
There is some curiosity that some patients (30%) with
histologically negative SLNB nevertheless still develop recurrent
disease and have a poor prognosis. Molecular studies may play a
role at this point. Attempts will be made to predict who these
patients are, using more specific markers.
If RT-PCR is adequately validated it is possible that the
protocol for sectioning and staining could become less extensive.
It seems likely that the need for S100 or Melan A will persist.
Other assessments may be needed since it is clear that the
status of the immunological reaction to the metastases in the
lymph node may be useful information when deciding upon
immunologically mediated therapy. Dendritic cells are one
component of this reaction that have been shown to correlate
with survival.30 Tumour infiltrating lymphocytes (TIL)22 in the
primary melanoma have prognostic significance in some studies.
TIL in metastases may have a similar significance.
Irrespective of the controversy that SLNB seems to provoke it
has stimulated much interesting analysis of the biological
processes involved in metastasis, some of which may result in
more beneficial therapy for the patients than the SLNB itself,
and therefore it is likely to remain an important part of the
management of melanoma patients for many years. It provides
a major opportunity for pathologists to play a pivotal role in
melanoma research and management.
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Take-home messages
c Sentinel lymph nodes merit detailed histological assessment
at several levels.
c Immunohistochemistry (S100 or MelanA) greatly facilitates
the recognition of metastases of melanoma.
c Additional prognostic information can be obtained by
assessing the sites and dimensions of metastases.
c Naevus cells occur in around 14% of sentinel lymph nodes and
need to be distinguished from metastatic melanoma.
My approach
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